MRK
Price
$148.31
Change
+$4.68 (+3.26%)
Updated
Oct 20, 04:59 PM (EDT)
Capitalization
354.36B
9 days until earnings call
Intraday BUY SELL Signals
SNY
Price
$41.40
Change
+$1.83 (+4.62%)
Updated
Oct 20 closing price
Capitalization
99.2B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MRK vs SNY

MRK vs SNY Comparison Chart in %
View a ticker or compare two or three
VS
MRK vs. SNY commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and SNY is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MRK with price predictions
Oct 19, 2026

Momentum Indicator for MRK turns positive, indicating new upward trend

MRK saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 52 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 193 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

MRK moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 25%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.451) is normal, around the industry mean (-3.218). MRK's P/E Ratio (113.992) is considerably higher than the industry average of (20.770). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.042) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).

A.I.Advisor
a Summary for SNY with price predictions
Oct 19, 2026

SNY's RSI Indicator recovers from oversold territory

The RSI Indicator for SNY moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 18 of the 27 cases the stock moved higher. This puts the odds of a move higher at 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 60 cases where SNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.

The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 55 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 25 of 48 cases over the following month. The odds of a continued upward trend are 52%.

Following a +2.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 156 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

SNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for SNY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (-3.218). P/E Ratio (25.167) is within average values for comparable stocks, (20.770). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.192) is considerably higher than the industry average of (0.042). P/S Ratio (1.829) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.

FUNDAMENTALS RATINGS
MRK vs SNY: Fundamental Ratings
MRK
SNY
OUTLOOK RATING
1..100
7217
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
3097
SMR RATING
1..100
7981
PRICE GROWTH RATING
1..100
3874
P/E GROWTH RATING
1..100
111
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (76) in the Pharmaceuticals Major industry is in the same range as MRK (88). This means that SNY’s stock grew similarly to MRK’s over the last 12 months.

MRK's Profit vs Risk Rating (30) in the Pharmaceuticals Major industry is significantly better than the same rating for SNY (97). This means that MRK’s stock grew significantly faster than SNY’s over the last 12 months.

MRK's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as SNY (81). This means that MRK’s stock grew similarly to SNY’s over the last 12 months.

MRK's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (74). This means that MRK’s stock grew somewhat faster than SNY’s over the last 12 months.

MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as SNY (11). This means that MRK’s stock grew similarly to SNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRKSNY
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
56%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 14 days ago
57%
Bullish Trend 5 days ago
51%
Declines
ODDS (%)
Bearish Trend 8 days ago
51%
Bearish Trend 8 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
62%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
51%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (MRK: $143.63 vs. SNY: $39.57)
Brand notoriety: MRK: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MRK: 100% vs. SNY: 129%
Market capitalization -- MRK: $354.36B vs. SNY: $99.2B
MRK [@Pharmaceuticals: Major] is valued at $354.36B. SNY’s [@Pharmaceuticals: Major] market capitalization is $99.2B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.11T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $203.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRK’s FA Score shows that 2 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).

  • MRK’s FA Score: 2 green, 3 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, MRK is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRK’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 6 bullish TA indicator(s).

  • MRK’s TA Score: 4 bullish, 3 bearish.
  • SNY’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, SNY is a better buy in the short-term than MRK.

Price Growth

MRK (@Pharmaceuticals: Major) experienced а -1.25% price change this week, while SNY (@Pharmaceuticals: Major) price change was -0.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.33%. For the same industry, the average monthly price growth was -4.81%, and the average quarterly price growth was +5.40%.

Reported Earning Dates

MRK is expected to report earnings on Oct 29, 2026.

SNY is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+3.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.